Company intelligence / Profile preview

PersImmune

California, United Statespersimmune.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

PersImmune is conducting a Phase 1 clinical trial of its PACTN platform targeting patient-specific neoantigens in myelodysplastic syndromes. Early results indicate completion of the first cohort without toxicity and approval to proceed to further cohorts. The company collaborates with major academic cancer centers for its ongoing studies[2].

Therapeutic areas: OncologyHematology
Modalities: Autologous T-cell therapyAdoptive cellular immunotherapy (personalized, non-genetically engineered T-cells)
Industry: Biotech

Drug pipeline

1 asset

PACTN

Phase 1

Indications: Myelodysplastic syndrome

Partnerships

UC San Diego Moores Cancer Center[1]UC Irvine Chao Family Comprehensive Cancer Center[1]

Beyond the preview

Go deeper on PersImmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PersImmune.

Explore the full profile